Clin Oncol | Volume 5, Issue 1 | Review Article | Open Access

A Beacon for Gynecological Cancers Patients: pH-Sensitive Nanomedicine

Pramod Vishwanath Prasad^1* and Anurag Srivastava²

¹Center for Biomedical Research, Population Council, The Rockefeller University, USA ²Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India

^*Correspondance to: Pramod Vishwanath Prasad 

Abstract

Emergence of various nanoscale drug carrier platforms as Drug Delivery Systems (DDS) has revolutionized the field of medicine. Nonetheless, the side-effects due to non-specific distribution of anticancer therapeutics in normal, healthy tissues remain to be a prime pitfall in curing cancers. Therefore,to achieve a better therapeutic efficacy the use of a target-specific delivery, combined with a stimuli-responsive nanocarrier system, particularly pH-sensitive nanosystems offer an attractive strategy. Targeted drug delivery through pH-sensitive nanosystems offer the potential to enhance the therapeutic index of anticancer agents either by increasing the drug concentration in tumor cells and/or by decreasing the exposure in normal host tissues. Therefore, nanoscale-based drug delivery through pH-sensitive nanosystems seem to be a boon for treating gynecological cancers (as well as other cancers) without side-effects or with least harm to normal health tissues

Citation:

Prasad PV, Srivastava A. A Beacon for Gynecological Cancers Patients: pHSensitive Nanomedicine. Clin Oncol. 2020;5:1681.